Catalyst Pharmaceuticals Inc — Cash Flow (NASDAQ:CPRX) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities 45.03 M60.37 M116.05 M143.6 M239.81 M208.67 M 208.67 M Cash from investing activities -5.01 M11.02 M9.21 M293.5 M556 K-58 K -6 000 Cash from financing activities 701.93 K8.14 M1.69 M10.86 M140.66 M-16.99 M -16.99 M Free cash flow 45.02 M59.35 M116.02 M143.37 M239.25 M208.61 M 208.61 M

Nouvelles

Oppenheimer réitère sa recommandation sur Catalyst Pharmaceutical après des revenus supérieurs aux attentes

Oppenheimer reiterates Catalyst Pharmaceutical stock rating on revenue beat

Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y

Le BPA de Catalyst Pharmaceuticals a dépassé les attentes de 0,37$, le CA a surpassé les prévisions

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

Stock Market Today: Dow Gains As Disney Dives, Pharma Play Eyes Entry, Oracle Pops On This (Live Coverage)

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

Jim Cramer: Crane Is A 'Good' Company, Recommends Holding This Tech Stock - Baker Hughes (NASDAQ:BKR), Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript